30006000330066003300660036007200
5T/box(Ⅰ-01)10T/box(Ⅰ-02)5T/box(Ⅱ-01)10T/box(Ⅱ-02)5T/box(Ⅲ-01)10T/box(Ⅲ-02)5T/box(Ⅳ-01)10T/box (IV-02)

30006000330066003300660036007200
5T/box(Ⅰ-01)10T/box(Ⅰ-02)5T/box(Ⅱ-01)10T/box(Ⅱ-02)5T/box(Ⅲ-01)10T/box(Ⅲ-02)5T/box(Ⅳ-01)10T/box (IV-02)
The first TRK inhibitor (larotrectinib) was approved for marketing by the FDA in 2018, targeting the NTRK tyrosine kinase region.NTRK is the gene that encodes TRK, and there are three family members, NTRK1, NTRK2, and NTRK3.NTRK gene translocations are the dosing target for larotrectinib.